International study on COVID-19 Vaccine to assess Immunogenicity, Reactogenicity and Efficacy (InVIT — SALLY HUNSBERGER (LEIDOS BI
This funding supports a multicenter study of COVID-19 vaccine immunogenicity and durability, and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections in people who receive a COVID-1
| Project title | International study on COVID-19 Vaccine to assess Immunogenicity, Reactogenicity and Efficacy (InVIT |
|---|---|
| Project number | 75N91019D00024-P00001-759102000025-3 |
| PI name | SALLY HUNSBERGER |
| Institution | LEIDOS BIOMEDICAL RESEARCH, INC. |
| Funding mechanism | N01 |
| Agency | NIAID |
| Award amount | $8.76M |
| Fiscal year | 2021 |
| Project start | 2020-09-28T00:00:00 |
| Project end | 2025-09-27T00:00:00 |
| Abstract | This funding supports a multicenter study of COVID-19 vaccine immunogenicity and durability, and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections in people who receive a COVID-1 |
| Key terms | <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><Age><Antibody Respon |
$799/mo
Try GrantRadar →